

Elizabeth M Swisher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8296988/publications.pdf>

Version: 2024-02-01

129
papers

14,102
citations

61984

43
h-index

20961

115
g-index

130
all docs

130
docs citations

130
times ranked

13406
citing authors

#	ARTICLE	IF	CITATIONS
1	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	13.7	1,261
2	Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 75-87.	10.7	975
3	Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. <i>Nature</i> , 2008, 451, 1116-1120.	27.8	934
4	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18032-18037.	7.1	814
5	Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. <i>Clinical Cancer Research</i> , 2014, 20, 764-775.	7.0	803
6	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2403-2415.	27.0	627
7	Inherited Mutations in Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 482.	7.1	576
8	Secondary Somatic Mutations Restoring <i>BRCA1/2</i> Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas. <i>Journal of Clinical Oncology</i> , 2011, 29, 3008-3015.	1.6	513
9	Secondary <i>BRCA1</i> Mutations in <i>BRCA1</i> -Mutated Ovarian Carcinomas with Platinum Resistance. <i>Cancer Research</i> , 2008, 68, 2581-2586.	0.9	435
10	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 12629-12633.	7.1	426
11	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 9-20.	4.9	408
12	Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. <i>JAMA Oncology</i> , 2019, 5, 1141.	7.1	355
13	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. <i>Cancer Discovery</i> , 2018, 8, 1404-1421.	9.4	311
14	Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 984-998.	9.4	310
15	Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. <i>Nature Communications</i> , 2018, 9, 1849.	12.8	310
16	Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. <i>Journal of Clinical Oncology</i> , 2015, 33, 1397-1406.	1.6	295
17	<i>BRCA</i> Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 210-219.	9.4	278
18	Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17041-17046.	7.1	225

#	ARTICLE	IF	CITATIONS
19	Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2017, 147, 267-275.	1.4	222
20	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202.	1.6	209
21	The BRCA1- \hat{P} 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. <i>Cancer Research</i> , 2016, 76, 2778-2790.	0.9	208
22	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. <i>Nature Communications</i> , 2018, 9, 3970.	12.8	192
23	Olaparib and \hat{I} -specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2019, 20, 570-580.	10.7	191
24	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. <i>Nature Communications</i> , 2020, 11, 1459.	12.8	176
25	Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. <i>Clinical Cancer Research</i> , 2018, 24, 777-783.	7.0	171
26	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 207-215.	10.7	167
27	Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic <i>TP53</i> mutations in noncancerous tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6005-6010.	7.1	135
28	Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. <i>Clinical Cancer Research</i> , 2020, 26, 4268-4279.	7.0	126
29	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Molecular Oncology</i> , 2014, 8, 656-668.	4.6	117
30	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 5651-5660.	7.0	116
31	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021, 12, 2487.	12.8	116
32	Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2005, 193, 662-667.	1.3	105
33	<i>BRCA1</i> , <i>TP53</i> , and <i>CHEK2</i> germline mutations in uterine serous carcinoma. <i>Cancer</i> , 2013, 119, 332-338.	4.1	99
34	Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. <i>Molecular Cancer</i> , 2009, 8, 48.	19.2	89
35	Somatic Mosaic Mutations in <i>PPM1D</i> and <i>TP53</i> in the Blood of Women With Ovarian Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 370.	7.1	88
36	Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. <i>Gynecologic Oncology</i> , 2019, 153, 192-200.	1.4	80

#	ARTICLE	IF	CITATIONS
37	RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. <i>Journal of Clinical Investigation</i> , 2016, 126, 3145-3157.	8.2	74
38	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	10.7	70
39	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. <i>Cell Reports</i> , 2018, 23, 100-111.	6.4	60
40	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. <i>Cell Reports</i> , 2021, 36, 109412.	6.4	60
41	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5508-5508.	1.6	60
42	In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 143, 379-388.	1.4	57
43	53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 153, 127-134.	1.4	56
44	Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma. <i>Gynecologic Oncology</i> , 2018, 148, 281-285.	1.4	52
45	TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. <i>Nucleic Acids Research</i> , 2015, 43, 6945-6958.	14.5	46
46	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. <i>Nature Communications</i> , 2019, 10, 5661.	12.8	45
47	Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	7.1	44
48	Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2021, 81, 4709-4722.	0.9	42
49	A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 6003-6003.	1.6	42
50	Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1001-1001.	1.6	40
51	Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2138-2147.	1.6	40
52	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. <i>Gynecologic Oncology</i> , 2019, 153, 217-222.	1.4	38
53	Characterization of splice-altering mutations in inherited predisposition to cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 26798-26807.	7.1	34
54	Rare BRIP1 Missense Alleles Confer Risk for Ovarian and Breast Cancer. <i>Cancer Research</i> , 2020, 80, 857-867.	0.9	33

#	ARTICLE	IF	CITATIONS
55	Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. <i>Gynecologic Oncology</i> , 2015, 137, 430-435.	1.4	32
56	<i>BRCA1</i> Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1190-1203.	6.3	32
57	Phase I/II study of olaparib and carboplatin in women with triple negative breast cancer. <i>Oncotarget</i> , 2017, 8, 79175-79187.	1.8	32
58	Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. <i>Journal of Clinical Oncology</i> , 2019, 37, 4014-4014.	1.6	29
59	BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. <i>EBioMedicine</i> , 2020, 60, 102988.	6.1	27
60	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. <i>PLoS ONE</i> , 2020, 15, e0234505.	2.5	25
61	Refinement of prespecified cutoff for genomic loss of heterozygosity (LOH) in ARIEL2 part 1: A phase II study of rucaparib in patients (pts) with high grade ovarian carcinoma (HGOC). <i>Journal of Clinical Oncology</i> , 2016, 34, 5540-5540.	1.6	25
62	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1879-1891.	1.6	25
63	Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. <i>Clinical Cancer Research</i> , 2016, 22, 3894-3902.	7.0	23
64	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. <i>Clinical Cancer Research</i> , 2021, 27, 6314-6322.	7.0	22
65	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1493-1499.	7.0	22
66	Usefulness of Multigene Testing. <i>JAMA Oncology</i> , 2015, 1, 951.	7.1	20
67	Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 602-613.	4.1	20
68	Characterization of a <i>RAD51C</i> -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance. <i>NAR Cancer</i> , 2021, 3, zcab028.	3.1	20
69	Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 163, 490-497.	1.4	20
70	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. <i>Cancers</i> , 2021, 13, 6385.	3.7	19
71	Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience. <i>Gynecologic Oncology</i> , 2020, 157, 514-520.	1.4	18
72	Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 691-703.	4.1	18

#	ARTICLE	IF	CITATIONS
73	Genetic characterization of early onset ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 140, 221-225.	1.4	17
74	Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. <i>Gynecologic Oncology</i> , 2021, 160, 786-792.	1.4	17
75	Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. <i>Gynecologic Oncology</i> , 2020, 156, 517-522.	1.4	16
76	Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. <i>Gynecologic Oncology</i> , 2022, 164, 245-253.	1.4	15
77	Genomic and epigenomic <i>BRCA</i> alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	15
78	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	1.4	14
79	Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations. <i>Gynecologic Oncology Reports</i> , 2019, 29, 113-117.	0.6	13
80	Results from MAGENTA: A national randomized four-arm noninferiority trial evaluating pre- and post-test genetic counseling during online testing for breast and ovarian cancer genetic risk.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1506-1506.	1.6	13
81	Phase I: Veliparib with cisplatin (CP) and vinorelbine (VNR) in advanced triple-negative breast cancer (TNBC) and/or BRCA mutation-associated breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2569-2569.	1.6	11
82	A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5519-5519.	1.6	11
83	Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 407-414.	1.4	10
84	More genes, more problems? Benefits and risks of multiplex genetic testing. <i>Gynecologic Oncology</i> , 2015, 139, 209-210.	1.4	9
85	Progesterone Receptors Promote Quiescence and Ovarian Cancer Cell Phenotypes via DREAM in p53-Mutant Fallopian Tube Models. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1929-1955.	3.6	9
86	ARIEL 2/3: An integrated clinical trial program to assess activity of rucaparib in ovarian cancer and to identify tumor molecular characteristics predictive of response.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS5619-TPS5619.	1.6	8
87	Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. <i>Cancer Prevention Research</i> , 2016, 9, 713-720.	1.5	7
88	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	2.5	7
89	Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2. <i>Gynecologic Oncology</i> , 2021, 161, 668-675.	1.4	7
90	PARP inhibitor maintenance for primary ovarian cancer – A missed opportunity for precision medicine. <i>Gynecologic Oncology</i> , 2021, 163, 11-13.	1.4	7

#	ARTICLE	IF	CITATIONS
91	Socioeconomic Status and Interest in Genetic Testing in a US-Based Sample. <i>Healthcare (Switzerland)</i> , 2022, 10, 880.	2.0	7
92	Ovarian carcinomas express HE4 epitopes independently of each other. <i>Cancer Treatment and Research Communications</i> , 2019, 21, 100152.	1.7	6
93	Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9065-9065.	1.6	6
94	Reflex test reminders in required cancer synoptic templates decrease order entry error: An analysis of mismatch repair immunohistochemical orders to screen for Lynch syndrome. <i>Journal of Pathology Informatics</i> , 2016, 7, 48.	1.7	6
95	Impact of veliparib, paclitaxel dosing regimen, and germline BRCA status on the primary treatment of serous ovarian cancer – an ancillary data analysis of the VELIA trial. <i>Gynecologic Oncology</i> , 2022, 164, 278-287.	1.4	6
96	Design of a study to implement population-based risk assessment for hereditary cancer genetic testing in primary care. <i>Contemporary Clinical Trials</i> , 2021, 101, 106257.	1.8	5
97	Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7-7.	1.6	5
98	Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006083.	1.2	5
99	Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas. <i>Gynecologic Oncology</i> , 2021, 163, 130-133.	1.4	5
100	Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1077-1077.	1.6	5
101	Identification of patients with ovarian cancer who are experiencing the highest benefit from bevacizumab in first-line setting based on their tumor intrinsic chemosensitivity (KELIM): GOG-0218 validation study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5553-5553.	1.6	5
102	Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention. <i>Familial Cancer</i> , 2020, 19, 143-151.	1.9	4
103	A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2602-2602.	1.6	4
104	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	2.8	4
105	Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2. <i>Current Women's Health Reports</i> , 2003, 3, 27-32.	0.2	4
106	Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer. <i>Current Treatment Options in Oncology</i> , 2003, 4, 105-110.	3.0	3
107	Premalignant alterations in breast and endometrium associated with a PTEN mutation in a woman with Cowden syndrome: implications for preventive care. <i>Gynecologic Oncology Reports</i> , 2015, 12, 13-16.	0.6	3
108	Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2016, 143, 389-392.	1.4	3

#	ARTICLE	IF	CITATIONS
109	DNA Repair Mutations and Outcomes in Ovarian Cancer's Response. <i>Clinical Cancer Research</i> , 2015, 21, 659-659.	7.0	2
110	Culprit or Bystander? The Role of the Fallopian Tube in Ovarian High-Grade Serous Carcinoma. <i>Cancer Discovery</i> , 2016, 6, 1309-1311.	9.4	2
111	Small cell ovarian carcinoma: Long term survival in juvenile case with poor prognostic features. <i>Gynecologic Oncology Reports</i> , 2016, 18, 45-48.	0.6	2
112	Doubling Down on BRCA -Mutated Cancer. <i>Trends in Cancer</i> , 2017, 3, 743-744.	7.4	2
113	Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years. <i>Gynecologic Oncology</i> , 2020, 159, 214-220.	1.4	2
114	Clinical characteristics and survival outcomes in BRCA1-methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5526-5526.	1.6	2
115	Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4147-TPS4147.	1.6	2
116	SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide (P/E) with or without atezolizumab (NSC#783608) in patients (pts) with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas (NEC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4179-TPS4179.	1.6	2
117	Targeting the C5 subclass of high-grade serous ovarian cancer using patient-derived xenografts: Microtubule polymerisation inhibitors.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22202-e22202.	1.6	1
118	A case of metastatic dysgerminoma treated with two cycles neoadjuvant chemotherapy followed by fertility-sparing minimally invasive surgery. <i>Gynecologic Oncology Reports</i> , 2019, 28, 124-127.	0.6	0
119	Preventing Breast Cancer in High-Risk Women: Is There Still a Role for Oophorectomy?. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz076.	2.9	0
120	Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8563-8563.	1.6	0
121	PolyG-DS: An ultrasensitive polyguanine tract profiling method to detect clonal expansions and trace cell lineage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2023373118.	7.1	0
122	Targeting therapy based on preclinical analysis of clinical, molecular, and functional characteristics of individual high-grade serous ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5073-5073.	1.6	0
123	Tumor biopsies in high grade ovarian cancer: Clinical utility and challenges for biomarker-directed therapy.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5539-5539.	1.6	0
124	The use of patient-derived xenograft models for prioritizing therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5579-5579.	1.6	0
125	53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5538-5538.	1.6	0
126	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0

#	ARTICLE	IF	CITATIONS
127	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
128	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
129	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0